MedTrace Logo

Iressa Follow-up Trial

NCT00357734 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2016-08-30

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the long-term safety profile and the secondary objective to estimate clinical benefit of ZD1839 (gefitinib).

Conditions

Interventions

DRUG

Gefitinib

ZD1839 at a daily dose of 250 mg or 500 mg depending on final dose in parent trial

Sponsors & Collaborators

Principal Investigators

  • AstraZeneca Germany Medical Director, MD · AstraZeneca

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2015-05-31
Completion
2015-05-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00357734 on ClinicalTrials.gov